131 related articles for article (PubMed ID: 8388232)
1. Analysis of the tumorigenic potential of common marmoset lymphoblastoid cells expressing a constitutively activated c-myc gene.
Hotchin NA; Wedderburn N; Roberts I; Thomas JA; Bungey JA; Naylor B; Crawford DH
Br J Cancer; 1993 May; 67(5):926-32. PubMed ID: 8388232
[TBL] [Abstract][Full Text] [Related]
2. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-infected marmoset cells transfected with c-myc do not form lymphomas in mice with severe combined immunodeficiency.
Salimi B; O'Gorman MR; Variakojis D; Bendet M; Newman M; Poupko E; Katz BZ
Mol Genet Metab; 1998 Jul; 64(3):205-12. PubMed ID: 9719630
[TBL] [Abstract][Full Text] [Related]
4. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
7. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
8. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
9. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
Kaptein JS; Lin CK; Wang CL; Nguyen TT; Kalunta CI; Park E; Chen FS; Lad PM
J Biol Chem; 1996 Aug; 271(31):18875-84. PubMed ID: 8702548
[TBL] [Abstract][Full Text] [Related]
10. Role of Epstein-Barr virus in Burkitt's lymphoma.
Takada K
Curr Top Microbiol Immunol; 2001; 258():141-51. PubMed ID: 11443859
[TBL] [Abstract][Full Text] [Related]
11. Deregulated c-myc expression in Epstein-Barr-virus-immortalized B-cells induces altered growth properties and surface phenotype but not tumorigenicity.
Hotchin NA; Allday MJ; Crawford DH
Int J Cancer; 1990 Mar; 45(3):566-71. PubMed ID: 2155186
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.
Lombardi L; Newcomb EW; Dalla-Favera R
Cell; 1987 Apr; 49(2):161-70. PubMed ID: 3032447
[TBL] [Abstract][Full Text] [Related]
13. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
15. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of C-myc increases the sensitivity of Epstein-Barr virus immortalized lymphoblastoid cells to non-MHC-restricted cytotoxicity.
Cuomo L; Zhang QJ; Lombardi L; Torsteinsdottir S; Klein G; Dalla-Favera R; Masucci MG
Int J Cancer; 1993 Apr; 53(6):1008-12. PubMed ID: 8386135
[TBL] [Abstract][Full Text] [Related]
17. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.
Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
Curr Top Microbiol Immunol; 2001; 258():153-60. PubMed ID: 11443860
[No Abstract] [Full Text] [Related]
18. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
19. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
20. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
